AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26896305 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of 25‐30 min of aerobic exercise
Number of subjects: 301
Study 26896305 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of 50‐60 min of aerobic exercise
Number of subjects: 301
Study 26896305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of 50‐60 min of aerobic and resistance exercise
Number of subjects: 301
Study 26896305 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume program (50‐60 min of aerobic exercise)
Number of subjects: 301
Study 24886116 — intervention group
Group type: EXPERIMENTAL
Intervention: BAcPAc (behavioural activation combined with physical activity promotion)
Number of subjects: 60
Study 24886116 — intervention group
Group type: COMPARATOR
Intervention: Behavioural activation alone (treatment as usual)
Number of subjects: 60
Study 24886116 — intervention group
Group type: EXPERIMENTAL
Intervention: BAcPAc
Number of subjects: 60
Study 24886116 — intervention group
Group type: COMPARATOR
Intervention: Behavioural activation alone
Number of subjects: 60
Study 23450712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI) delivered in up to eight weekly telephone sessions (CBTI-Phone, n = 15)
Number of subjects: 30
Study 23450712 — intervention group
Group type: COMPARATOR
Intervention: Information pamphlet control (IPC, n = 15)
Number of subjects: 30
Study 20518172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and non-scarring moxibustion (applied on local acupoints of knee, Shenshu (BL 23), and Xuehai (SP 10))
Number of subjects: 62
Study 20518172 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (only)
Number of subjects: 62
Study 20518172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 62
Study 18809424 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold processing of global stimuli for motion and spatial tasks
Number of subjects: 0
Study 16907968 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy (measured by the Short‐Test of Functional Health Literacy in Adults)
Number of subjects: 1002
Study 14509171 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy (Tele‐Otoscope with a 70 degrees viewing angle) used as an intraoperative visualization aid
Number of subjects: 129
Study 14509171 — intervention group
Group type: COMPARATOR
Intervention: Micromirrors used for intraoperative diagnostics
Number of subjects: 129
Study 10641779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal epoetin alfa
Number of subjects: 20
Study 10641779 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa
Number of subjects: 20
Study 8648396 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 8648396 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF)
Number of subjects: 0
Study 8648396 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFs (GM-CSF or G-CSF) administered before or during induction therapy and following chemotherapy until neutrophil recovery
Number of subjects: 0
Study 1794947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 1794947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3918430 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial beta-galactosidases added to 360 ml of cow milk containing 18 g of lactose
Number of subjects: 0
Study 3918430 — intervention group
Group type: COMPARATOR
Intervention: Intact milk
Number of subjects: 0
Study 31374252 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (peer-to-peer consultation program)
Number of subjects: 0
Study 31374252 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 29757058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing THR or TKR
Number of subjects: 587
Study 29757058 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients (well-controlled vs poorly-controlled)
Number of subjects: 587
Study 29178716 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing lysozyme
Number of subjects: 71
Study 29178716 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 71
Study 24001105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.2 mg
Number of subjects: 223
Study 24001105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.5 mg
Number of subjects: 223
Study 24001105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.8 mg
Number of subjects: 223
Study 24001105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 22752418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1 )day(‐1) ferrous sulfate for 6 months starting at 6 months of age
Number of subjects: 105
Study 22752418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 105
Study 20863759 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN resection plus ALND (group 1)
Number of subjects: 3989
Study 20863759 — intervention group
Group type: COMPARATOR
Intervention: SLN resection alone (group 2)
Number of subjects: 3989
Study 17913720 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg every 12 h)
Number of subjects: 151
Study 17913720 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g every 12 h)
Number of subjects: 151
Study 16148176 — intervention group
Group type: EXPERIMENTAL
Intervention: HpSA test (Equipar)
Number of subjects: 430
Study 16148176 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-based tests
Number of subjects: 430
Study 14607200 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Ribose
Number of subjects: 15
Study 14607200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10837450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0
Study 10837450 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study 8646953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 20
Study 8646953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1826046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan (100 mg/day) for six months
Number of subjects: 145
Study 1826046 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-platelet treatment for six months
Number of subjects: 145
Study 6372065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (Surmontil), 50 mg at bedtime
Number of subjects: 114
Study 6372065 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Tagamet), 200 + 200 + 200 + 400 mg/day
Number of subjects: 114
Study 30205182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1× per week exercise
Number of subjects: 0
Study 30205182 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× per week exercise
Number of subjects: 0
Study 30205182 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 28854588 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 SET + Eeva™
Number of subjects: 163
Study 28854588 — intervention group
Group type: EXPERIMENTAL
Intervention: D5 SET + Eeva™
Number of subjects: 163
Study 28854588 — intervention group
Group type: COMPARATOR
Intervention: D5 SET with CM alone
Number of subjects: 163
Study 25831203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler circumcision
Number of subjects: 879
Study 25831203 — intervention group
Group type: COMPARATOR
Intervention: Conventional circumcision
Number of subjects: 879
Study 23210859 — intervention group
Group type: EXPERIMENTAL
Intervention: Solobond M two‐step etch‐and‐rinse adhesive
Number of subjects: 244
Study 23210859 — intervention group
Group type: COMPARATOR
Intervention: Futurabond NR one‐step self‐etch adhesive
Number of subjects: 244
Study 21054750 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ATC
Number of subjects: 51
Study 21054750 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ATC
Number of subjects: 51
Study 21054750 — intervention group
Group type: COMPARATOR
Intervention: 150 mg 3TC
Number of subjects: 51
Study 18506177 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 2300 hours
Number of subjects: 44
Study 18506177 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 1100 hours
Number of subjects: 44
Study 18506177 — intervention group
Group type: COMPARATOR
Intervention: Control group (morning administration)
Number of subjects: 44
Study 16984725 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacking habit
Number of subjects: 0
Study 16984725 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual negative self‐thinking
Number of subjects: 0
Study 16984725 — intervention group
Group type: EXPERIMENTAL
Intervention: Task complexity manipulation
Number of subjects: 0
Study 12853354 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 125 mg/m(2), FA 20 mg/m(2) followed by 5‐FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A)
Number of subjects: 154
Study 12853354 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 180 mg/m(2) day 1, FA 200 mg/m(2) over 2 h and 5‐FU 400 mg/m(2) bolus and 5‐FU 600 mg/m(2) 22‐h infusion on days 1 and 2, every 2 weeks (arm B)
Number of subjects: 154
Study 12853354 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5‐FU bolus 425 mg/m(2)/day during 5 days (days 22‐26) (arm C)
Number of subjects: 154
Study 10778842 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete EMRs
Number of subjects: 16
Study 10778842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid EMRs
Number of subjects: 16
Study 10778842 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study 8780093 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injections
Number of subjects: 66
Study 8780093 — intervention group
Group type: COMPARATOR
Intervention: Trihexyphenidyl tablets plus placebo injection
Number of subjects: 66
Study 1633721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1000 mg twice daily
Number of subjects: 305
Study 1633721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg twice daily
Number of subjects: 305
Study 1633721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg twice daily
Number of subjects: 305
Study 1633721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg twice daily
Number of subjects: 305
Study 1633721 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 10 mg/kg 3-times daily
Number of subjects: 305
Study 1633721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg twice daily (elderly subgroup)
Number of subjects: 305
Study 6360751 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg i.v.
Number of subjects: 60
Study 6360751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg i.v.
Number of subjects: 60
Study 6360751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31455149 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Education Program (SPEP)
Number of subjects: 140
Study 31455149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 29696654 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey proteins
Number of subjects: 21
Study 29696654 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 21
Study 29696654 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed casein
Number of subjects: 21
Study 27545050 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS augmentation (Restore Orthobiologic Implant; DePuy, Warsaw, IN, USA)
Number of subjects: 62
Study 27545050 — intervention group
Group type: COMPARATOR
Intervention: Control (repair alone)
Number of subjects: 62
Study 27545050 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS augmentation
Number of subjects: 62
Study 25433525 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex self-management intervention
Number of subjects: 436
Study 23260038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support provided by a registered nurse
Number of subjects: 40
Study 23260038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 40
Study 20838333 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated dispensing system
Number of subjects: 115
Study 20838333 — intervention group
Group type: COMPARATOR
Intervention: Control unit (no automated dispensing system)
Number of subjects: 115
Study 17440529 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale meal (150 g)
Number of subjects: 16
Study 17440529 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale meal with potassium oxalate drink (150 g kale + 1.26 g OA)
Number of subjects: 16
Study 17440529 — intervention group
Group type: COMPARATOR
Intervention: Spinach meal (150 g)
Number of subjects: 16
Study 16913827 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 70
Study 16913827 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol
Number of subjects: 70
Study 12025521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (initial dose 50 mg taken 1 h before sexual activity for the first 2 weeks, increased to 100 mg or decreased to 25 mg as needed)
Number of subjects: 60
Study 12025521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12025521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 60
Study 12025521 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil and Placebo
Number of subjects: 60
Study 10396381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen at the central cornea
Number of subjects: 48
Study 10396381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen at the mid-peripheral cornea
Number of subjects: 48
Study 10396381 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 48
Study 10396381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-peripheral corneal thickness
Number of subjects: 48
Study 10396381 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness
Number of subjects: 48
Study 7486360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 20 mg orally every 12 hours for 4 days
Number of subjects: 43
Study 7486360 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally every 12 hours for 4 days
Number of subjects: 43
Study 2151970 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser thermal angioplasty
Number of subjects: 25
Study 2151970 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 25
Study 7419005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 130
Study 29808473 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (HA-PVX)
Number of subjects: 12
Study 29808473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (HA-SIL)
Number of subjects: 12
Study 29808473 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion with Sildenafil (HA-PVX-SIL)
Number of subjects: 12
Study 29808473 — intervention group
Group type: COMPARATOR
Intervention: High Altitude (HA)
Number of subjects: 12
Study 28423305 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based screening schedule for retinopathy based on current state of retinopathy and glycated hemoglobin levels.
Number of subjects: 1000
Study 28423305 — intervention group
Group type: COMPARATOR
Intervention: Routine annual examinations for retinopathy.
Number of subjects: 1000
Study 28423305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no retinopathy and glycated hemoglobin level of 6%.
Number of subjects: 1000
Study 28423305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild retinopathy and glycated hemoglobin level of 10%.
Number of subjects: 1000
Study 28423305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate retinopathy.
Number of subjects: 1000
Study 28423305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe nonproliferative diabetic retinopathy.
Number of subjects: 1000
Study 24256085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges stroke self-management program (one session of up to one hour per week for six weeks)
Number of subjects: 25
Study 24256085 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation only
Number of subjects: 25
Study 25031133 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2-1 mg/kg/d)
Number of subjects: 69
Study 25031133 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.2 mg/kg/d)
Number of subjects: 69
Study 20934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10mg
Number of subjects: 63
Study 20934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 40mg
Number of subjects: 63
Study 20934481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19243708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1818
Study 19243708 — intervention group
Group type: COMPARATOR
Intervention: Non-TZD (comparator)
Number of subjects: 1818
Study 17316102 — intervention group
Group type: COMPARATOR
Intervention: Standard training (reading directions for use and trying on their own)
Number of subjects: 102
Study 17316102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training (individual coaching and inspiratory flow rate training)
Number of subjects: 102
Study 15446320 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 60
Study 15446320 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 60
Study 11135384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidromic transcutaneous sacral neurostimulation during the second fill (n = 74)
Number of subjects: 146
Study 11135384 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent a second fill without neurostimulation (n = 72)
Number of subjects: 146
Study 9874288 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PCR assay combined with immunological and colorimetric detection of bcr-rearrangement
Number of subjects: 7
Study 9874288 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 7
Study 8665709 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring group (n=17)
Number of subjects: 31
Study 8665709 — intervention group
Group type: COMPARATOR
Intervention: Control group (cadaveric specimens, n=14)
Number of subjects: 31
Study 2393014 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL regular coffee
Number of subjects: 6
Study 2393014 — intervention group
Group type: EXPERIMENTAL
Intervention: 165 mL regular coffee
Number of subjects: 6
Study 2393014 — intervention group
Group type: COMPARATOR
Intervention: 165 mL decaffeinated coffee
Number of subjects: 6
Study 2393014 — intervention group
Group type: COMPARATOR
Intervention: 165 mL sodium chloride solution
Number of subjects: 6
Study 343630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 93
Study 343630 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 93
Study 343630 — intervention group
Group type: COMPARATOR
Intervention: 0.375% bupivacaine
Number of subjects: 93
Study 30373802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 800 mg
Number of subjects: 97
Study 30373802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 4000 mg
Number of subjects: 97
Study 30373802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 1500 mg
Number of subjects: 97
Study 30373802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 3000 mg
Number of subjects: 97
Study 30373802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Number of subjects: 97
Study 28025216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 2500
Study 28025216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 26311500 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 144
Study 26311500 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (among conscious patients)
Number of subjects: 144
Study 26311500 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (among unconscious patients)
Number of subjects: 144
Study 26311500 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 144
Study 23696054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus steroids (ST)
Number of subjects: 75
Study 23696054 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus mycophenolate mofetil (MMF)
Number of subjects: 75
Study 21310910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 mL, given as three initial treatments with further retreatment as needed)
Number of subjects: 131
Study 21310910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 131
Study 21310910 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 131
Study 19854514 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 118
Study 17142654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g iv every six hours plus oral placebo (group A)
Number of subjects: 45
Study 17142654 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg po every six hours plus iv placebo (group I)
Number of subjects: 45
Study 14617059 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexamethazone (3 ml)
Number of subjects: 25
Study 14617059 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis with saline solution (3 ml)
Number of subjects: 25
Study 10385137 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 15538
Study 10385137 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 15538